GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Additional Paid-In Capital

NLS Pharmaceutics (NLS Pharmaceutics) Additional Paid-In Capital : $61.03 Mil(As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Additional Paid-In Capital?


NLS Pharmaceutics's quarterly additional paid-in capital increased from Dec. 2022 ($60.87 Mil) to Jun. 2023 ($60.93 Mil) and increased from Jun. 2023 ($60.93 Mil) to Dec. 2023 ($61.03 Mil).

NLS Pharmaceutics's annual additional paid-in capital increased from Dec. 2021 ($42.09 Mil) to Dec. 2022 ($60.87 Mil) and increased from Dec. 2022 ($60.87 Mil) to Dec. 2023 ($61.03 Mil).

NLS Pharmaceutics Additional Paid-In Capital Historical Data

The historical data trend for NLS Pharmaceutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Additional Paid-In Capital Chart

NLS Pharmaceutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 20.60 20.65 42.09 60.87 61.03

NLS Pharmaceutics Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.09 45.96 60.87 60.93 61.03

NLS Pharmaceutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

NLS Pharmaceutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Additional Paid-In Capital
Comparable Companies
UNCY NBIO AIM SKYE ELEV ACST NTBL BIXT VINC ACER OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
The Circle 6, Zurich, CHE, 8058
Website
https://www.nlspharma.com
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.